chlorotrianisene

Key facts

INN

chlorotrianisene

Brand

TACE

Route

ORAL

Formulation

CAPSULE

Related patents

patent

US 9346866

Inhibition of tace activity with cyclic peptides

Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

patent

US 8168588

Compositions comprising FGF-9 and betacellulin and methods for treating cardiac

Expires Mon Apr 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

patent

US 7919520

Inhibitors of tace

Expires Mon Mar 31 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

patent

US 7485664

Inhibitors of TACE

Expires Mon Jan 29 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

patent

US 6825165

Betacellulin modification

Expires Mon Nov 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

patent

US 6183971

Human betacellulin-specific antibodies and uses thereof

Expires Mon Feb 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Frequently asked questions

What is chlorotrianisene?

chlorotrianisene (TACE), is a pharmaceutical active ingredient, with approved status in the US.

What is the brand name for chlorotrianisene?

TACE is a marketed brand name for chlorotrianisene. Check FDA Drugs@FDA for the current US label holder.